Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Last Price: 1.22 (2020-11-30)

Company Description

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $36.14M
Net Income (Most Recent Fiscal Year) $-71.45M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 17.52
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 3.41
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -2208.06%
Net Margin (Trailing 12 Months) -2208.06%
Return on Equity (Trailing 12 Months) -485.45%
Return on Assets (Trailing 12 Months) -167.68%
Current Ratio (Most Recent Fiscal Quarter) 2.06
Quick Ratio (Most Recent Fiscal Quarter) 2.06
Debt to Common Equity (Most Recent Fiscal Quarter) 0.61
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $0.10
Earnings per Share (Most Recent Fiscal Quarter) $-0.43
Earnings per Share (Most Recent Fiscal Year) $-1.12
Diluted Earnings per Share (Trailing 12 Months) $-1.79
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 84.04M
Free Float 77.15M
Market Capitalization $102.53M
Average Volume (Last 20 Days) 3.77M
Beta (Past 60 Months) 2.10
Percentage Held By Insiders (Latest Annual Proxy Report) 8.20%
Percentage Held By Institutions (Latest 13F Reports) 71.18%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%